Reuters logo
BRIEF-VBL Therapeutics announces positive outcome in third, final DSMC review of phase 3 globe trial investigating VB-111 in recurrent GBM
October 2, 2017 / 11:36 AM / 16 days ago

BRIEF-VBL Therapeutics announces positive outcome in third, final DSMC review of phase 3 globe trial investigating VB-111 in recurrent GBM

Oct 2 (Reuters) - Vascular Biogenics Ltd:

* VBL Therapeutics announces positive outcome in the third and final dsmc review of phase 3 globe trial investigating vb-111 in recurrent GBM

* Vascular Biogenics Ltd - ‍dsmc confirmed that no additional follow up will be necessary

* Vascular Biogenics Ltd - ‍dsmc unanimously recommended that study continue as planned, to completion​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below